Eilsberger Friederike, Kreissl Michael C, Luster Markus, Pfestroff Andreas
Klinik für Nuklearmedizin, Universitätsklinikum Marburg, Marburg, Germany.
Abteilung für Nuklearmedizin, Universitatsklinikum Magdeburg, Magdeburg, Germany.
Nuklearmedizin. 2022 Jun;61(3):223-230. doi: 10.1055/a-1650-9762. Epub 2022 Jun 3.
Theranostics via the sodium iodide symporter (NIS) offer a unique option in differentiated thyroid carcinoma. The diagnostic and therapeutic nuclides have similar uptake and kinetics, making the NIS the most important theranostic target in this disease. Radioiodine refractory thyroid carcinomas (RRTC) are characterised by reduced/absent NIS expression, thus eliminating this structure as a theranostic target. Also due to limited therapeutic options, there are approaches to generate new theranostic targets in RRTC, via the expression of somatostatin receptors (SSTR) or the prostate-specific membrane antigen (PSMA), but the current evidence does not yet allow a final evaluation of the prospects of success.
通过碘化钠同向转运体（NIS）进行的诊疗一体化为分化型甲状腺癌提供了一种独特的选择。诊断性和治疗性核素具有相似的摄取和动力学特性，使得NIS成为这种疾病最重要的诊疗靶点。放射性碘难治性甲状腺癌（RRTC）的特征是NIS表达降低/缺失，因此消除了这个结构作为诊疗靶点的可能性。同样由于治疗选择有限，有一些方法可通过生长抑素受体（SSTR）或前列腺特异性膜抗原（PSMA）的表达在RRTC中产生新的诊疗靶点，但目前的证据还无法对成功前景进行最终评估。
